Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies (drugs and devices) designed to address the significant needs of critically ill patients. The company’s lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package is marketed in the USA, Puerto Rico, Canada, Australia, Mexico and Japan
View Top Employees from IKARWebsite | http://www.ikaria.com |
Employees | 87 (31 on RocketReach) |
Founded | 2007 |
Phone | (908) 238-6600 |
Technologies |
Slack,
Shopify,
Microsoft Project
+13 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Biotechnology, Hospitals/Inpatient Services, Hypoxic Respiratoty Failure, Science and Engineering, Other Healthcare Services, Cardiac Remodeling post AMI (prevent CHF), Medical, Hepato-Renal Syndrome, Health Care, Pulmonary Arterial Hypertension (PAH), Therapeutics, Pulmonary Hypertension Secondary to COPD |
Web Rank | 837451 |
Keywords | Mallinckrodt, Mallinckrodt Pharmaceuticals, Mallinckrodt Investor Relations, Stratatech, Specgx |
Looking for a particular IKAR employee's phone or email?
Todd Dixon is the Vice President, Operations of IKAR.
31 people are employed at IKAR.